Acrivon Therapeutics (ACRV) Competitors $6.50 +0.12 (+1.88%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACRV vs. ERAS, AUTL, EOLS, PLRX, CRON, CGEM, PRTA, REPL, CRGX, and AVXLShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Erasca (ERAS), Autolus Therapeutics (AUTL), Evolus (EOLS), Pliant Therapeutics (PLRX), Cronos Group (CRON), Cullinan Therapeutics (CGEM), Prothena (PRTA), Replimune Group (REPL), CARGO Therapeutics (CRGX), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Erasca Autolus Therapeutics Evolus Pliant Therapeutics Cronos Group Cullinan Therapeutics Prothena Replimune Group CARGO Therapeutics Anavex Life Sciences Erasca (NASDAQ:ERAS) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Does the MarketBeat Community believe in ERAS or ACRV? Acrivon Therapeutics received 9 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 97.06% of users gave Acrivon Therapeutics an outperform vote while only 70.59% of users gave Erasca an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes2470.59% Underperform Votes1029.41% Acrivon TherapeuticsOutperform Votes3397.06% Underperform Votes12.94% Do analysts rate ERAS or ACRV? Erasca currently has a consensus target price of $6.08, indicating a potential upside of 130.43%. Acrivon Therapeutics has a consensus target price of $23.67, indicating a potential upside of 264.10%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ERAS or ACRV more profitable? Erasca's return on equity of -42.26% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Acrivon Therapeutics N/A -47.95%-43.73% Does the media favor ERAS or ACRV? In the previous week, Acrivon Therapeutics had 2 more articles in the media than Erasca. MarketBeat recorded 17 mentions for Acrivon Therapeutics and 15 mentions for Erasca. Erasca's average media sentiment score of 0.80 beat Acrivon Therapeutics' score of 0.00 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ERAS or ACRV? Erasca has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Which has higher valuation & earnings, ERAS or ACRV? Erasca is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.83-3.18Acrivon TherapeuticsN/AN/A-$60.39M-$2.70-2.41 Do insiders and institutionals believe in ERAS or ACRV? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 21.5% of Erasca shares are owned by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAcrivon Therapeutics beats Erasca on 9 of the 15 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.65M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-2.414.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book1.0310.126.936.25Net Income-$60.39M$153.61M$119.12M$225.93M7 Day Performance-17.93%-2.00%-1.83%-1.32%1 Month Performance-19.25%-7.47%-3.64%0.60%1 Year Performance79.06%31.80%31.64%26.23% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.7362 of 5 stars$6.50+1.9%$23.67+264.1%+62.9%$198.65MN/A-2.4158Analyst RevisionERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$788.81MN/A0.00126Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.4682 of 5 stars$2.80-5.1%$10.15+262.5%-36.5%$784.98M$1.70M0.00330Analyst UpgradeEOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$784.55M$202.09M0.00170Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090CRONCronos Group1.7856 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$776.06M$87.24M-15.46356CGEMCullinan Therapeutics1.8234 of 5 stars$12.58-4.0%$31.67+151.7%+43.6%$762.78M$18.94M0.0030Analyst RevisionPRTAProthena1.6436 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.01M$91.37M0.00173Analyst DowngradeAnalyst RevisionREPLReplimune Group4.2429 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A0.00210CRGXCARGO Therapeutics1.6683 of 5 stars$15.82-1.8%$30.33+91.7%+8.0%$741.51MN/A-3.71116AVXLAnavex Life Sciences3.7023 of 5 stars$8.48+2.8%$40.00+372.0%+21.1%$698.72MN/A0.0040Upcoming Earnings Related Companies and Tools Related Companies Erasca Competitors Autolus Therapeutics Competitors Evolus Competitors Pliant Therapeutics Competitors Cronos Group Competitors Cullinan Therapeutics Competitors Prothena Competitors Replimune Group Competitors CARGO Therapeutics Competitors Anavex Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
